In summary, overlapping syndromes deepen the need to actively seek the presence of LMNA mutations in subjects with clinical features of partial lipodystrophy, cardiac abnormalities, or certain types of myopathy, in order to prevent, as far as possible, their potentially lethal consequences. This evidence concerns the gene LMNA and partial lipodystrophy.